However, in the TCGA cohort examined in our study, we found that BRCA mutations are represented in as many as 11.5% of cutaneous melanoma patients, with many patients also harboring mutations to ATM, BRIP1, CHECK2, DMC1, FANCD2, FANCM, and POLQ. As 37.5% of this patient cohort had at least one mutation affecting the HR pathway, the use of these and other mutations warrant consideration when exploring PARP inhibitors in subsequent clinical trials. Here, DMC1 is linked to cutaneous melanoma.